BACKGROUND. 2',3'-Dideoxyinosine (ddl) is a dideoxynucleoside with potent activity in vitro against the human immunodeficiency virus (HIV). In initial clinical trials in adults, ddl showed evidence of antiretroviral activity with little hematologic toxicity. METHODS. We conducted a phase I-II study in 43 children with symptomatic (CDC class P-2) HIV infection. Of these children, 16 (median age, 10 years) had previously received zidovudine, and 27 (median age, 2.6 years) had not. ddl was administered orally in three divided doses totalling 60, 120, 180, 360, or 540 mg per square meter of body-surface area per day for 24 weeks. Eight of the 43 patients did not complete 24 weeks of ddl: 6 died, 1 was withdrawn because of progressive disease, and the other because of toxicity. RESULTS. After oral administration, ddl was rapidly absorbed, although its bioavailability varied greatly among patients. Pancreatitis developed in two children, one receiving ddl at each of the two highest doses. The median CD4 cell count in 38 patients with paired counts increased from 0.218 x 10(9) per liter (218 per cubic millimeter) at base line to 0.327 x 10(9) per liter (327 per cubic millimeter) after 20 to 24 weeks (P = 0.001). Those with CD4 cell counts above 0.1 x 10(9) per liter (100 per cubic millimeter) at base line were significantly more likely to improve in this respect. The median levels of p24 antigen (in 27 patients with detectable levels at entry) declined from 272 pg per milliliter at base line to 77 pg per milliliter at 20 to 24 weeks (P = 0.005). The plasma concentration of ddl correlated significantly with both the degree of decline in the p24 antigen and the degree of improvement in IQ score. Improvement in clinical and immunologic measures occurred in both the previously untreated patients and in those who had been treated with zidovudine. CONCLUSIONS. Dideoxyinosine was well tolerated and showed promising antiretroviral activity in HIV-infected children. The correlation between the clinical response and the plasma concentration of ddl indicates that bioavailability is an important consideration in the use of ddl to treat HIV infection and that individualized pharmacokinetic monitoring and dose adjustment may be important for optimal activity.
Source Information
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md 20892.
This article has been cited by other articles:
Hirt, D., Bardin, C., Diagbouga, S., Nacro, B., Hien, H., Zoure, E., Rouet, F., Ouiminga, A., Urien, S., Foulongne, V., Van De Perre, P., Treluyer, J.-M., Msellati, P.
(2009). Didanosine Population Pharmacokinetics in West African Human Immunodeficiency Virus-Infected Children Administered Once-Daily Tablets in Relation to Efficacy after One Year of Treatment. Antimicrob. Agents Chemother.
53: 4399-4406
[Abstract][Full Text]
Wilmshurst, J. M., Burgess, J., Hartley, P., Eley, B.
(2006). Specific Neurologic Complications of Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Children. J Child Neurol
21: 788-794
[Abstract]
Gwilt, P. R., Manouilov, K. K., McNabb, J., Swindells, S. S.
(2003). Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV-1-Infected Patients. J Clin Pharmacol
43: 1003-1007
[Abstract][Full Text]
Savolainen, J., Edwards, J. E., Morgan, M. E., McNamara, P. J., Anderson, B. D.
(2002). Effects of a P-Glycoprotein Inhibitor on Brain and Plasma Concentrations of Anti-Human Immunodeficiency Virus Drugs Administered in Combination in Rats. Drug Metab. Dispos.
30: 479-482
[Abstract][Full Text]
Resino, S, Bellon, J M, Sanchez-Ramon, S, Gurbindo, D, Ruiz-Contreras, J, Leon, J A, Ramos, J T, Munoz-Fernandez, M A
(2002). Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch. Dis. Child.
86: 119-124
[Abstract][Full Text]
Li, J. Y., Boado, R. J., Pardridge, W. M.
(2001). Differential Kinetics of Transport of 2',3'-Dideoxyinosine and Adenosine via Concentrative Na+ Nucleoside Transporter CNT2 Cloned from Rat Blood-Brain Barrier. J. Pharmacol. Exp. Ther.
299: 735-740
[Abstract][Full Text]
Sáez-Llorens, X., Nelson Jr, R. P., Emmanuel, P., Wiznia, A., Mitchell, C., Church, J. A., Sleasman, J., Van Dyke, R., Richardson, C. G., Cutrell, A., Spreen, W., Hetherington, S., the CNAA3006 Study Team,
(2001). A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children. Pediatrics
107: 4e-4
[Abstract][Full Text]
Abreu, T., Plaisance, K., Rexroad, V., Nogueira, S., Oliveira, R. H., Evangelista, L. A., Rangel, R., Silva, I. S., Knupp, C., Lambert, J. S.
(2000). Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children. Antimicrob. Agents Chemother.
44: 1375-1376
[Abstract][Full Text]
Fletcher, C. V., Brundage, R. C., Remmel, R. P., Page, L. M., Weller, D., Calles, N. R., Simon, C., Kline, M. W.
(2000). Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy. Antimicrob. Agents Chemother.
44: 1029-1034
[Abstract][Full Text]
Raskino, C., Pearson, D. A., Baker, C. J., Lifschitz, M. H., O'Donnell, K., Mintz, M., Nozyce, M., Brouwers, P., McKinney, R. E., Jimenez, E., Englund, J. A., for the Pediatric AIDS Clinical Trials Group 152 S,
(1999). Neurologic, Neurocognitive, and Brain Growth Outcomes in Human Immunodeficiency Virus-Infected Children Receiving Different Nucleoside Antiretroviral Regimens. Pediatrics
104
: e32-e32
[Abstract][Full Text]
(1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics
102: 1005-1062
[Full Text]
Tashima, K. T.
(1998). Cerebrospinal Fluid Levels of Antiretroviral Medications: Abstract and Commentary. JAMA
280: 879-880
[Full Text]
Mueller, B. U., Nelson Jr, R. P., Sleasman, J., Zuckerman, J., Heath-Chiozzi, M., Steinberg, S. M., Balis, F. M., Brouwers, P., Hsu, A., Saulis, R., Sei, S., Wood, L. V., Zeichner, S., Katz, T. T. K., Higham, C., Aker, D., Edgerly, M., Jarosinski, P., Serchuck, L., Whitcup, S. M., Pizzuti, D., Pizzo, P. A.
(1998). A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection. Pediatrics
101: 335-343
[Abstract][Full Text]
Landry, K., Smith, T.
(1998). Neurocognitive Effects of HIV Infection on Young Children: Implications for Assessment. Topics in Early Childhood Special Education
18: 160-169
[Abstract]
Vreugdenhil, H., Brouwers, P., Wolters, P., Bakker, D., Moss, H.
(1997). Spontaneous Eye Blinking, a Measure of Dopaminergic Function, in Children With Acquired Immunodeficiency Syndrome. Arch Pediatr Adolesc Med
151: 1025-1032
[Abstract]
Englund, J. A., Baker, C. J., Raskino, C., McKinney, R. E., Petrie, B., Fowler, M. G., Pearson, D., Gershon, A., McSherry, G. D., Abrams, E. J., Schliozberg, J., Sullivan, J. L., Behrman, R., Connor, J. C., Hetherington, S., Lifschitz, M. H., McLaren, C., Mendez, H., Millison, K., Moye, J., Nozyce, M., O'Donnell, K., Purdue, L., Schoenfeld, D., Scott, G., Spector, S. A., Wara, D. W., The AIDS Clinical Trials Group (ACTG) Study 152 Te,
(1997). Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children. NEJM
336: 1704-1712
[Abstract][Full Text]
Brouwers, P., DeCarli, C., Civitello, L., Moss, H., Wolters, P., Pizzo, P.
(1995). Correlation Between Computed Tomographic Brain Scan Abnormalities and Neuropsychological Function in Children With Symptomatic Human Immunodeficiency Virus Disease. Arch Neurol
52: 39-44
[Abstract]
Whitcup, S. M., Dastgheib, K., Nussenblatt, R. B., Walton, R. C., Pizzo, P. A., Chan, C.-C.
(1994). A Clinicopathologic Report of the Retinal Lesions Associated With Didanosine. Arch Ophthalmol
112: 1594-1598
[Abstract]
Gerber, A. R., Valdiserri, R. O., Holtgrave, D. R., Jones, T. S., West, G. R., Hinman, A. R., Curran, J. W.
(1993). Preventive Services Guidelines for Primary Care Clinicians Caring for Adults and Adolescents Infected With the Human Immunodeficiency Virus. Arch Fam Med
2: 969-979
[Abstract]
Hirsch, M. S., D'Aquila, R. T.
(1993). Therapy for Human Immunodeficiency Virus Infection. NEJM
328: 1686-1695
[Full Text]
LANDOR, M., BERNSTEIN, L., RUBINSTEIN, A.
(1993). A Steroid-Responsive Nephropathy in a Child With Human Immunodeficiency Virus Infection. Arch Pediatr Adolesc Med
147: 261-262
[Abstract]
Butler, K. M., Husson, R. N., Lewis, L. L., Mueller, B. U., Venzon, D., Pizzo, P. A.
(1992). CD4 Status and P24 Antigenemia: Are They Useful Predictors of Survival in HIV-Infected Children Receiving Antiretroviral Therapy?. Arch Pediatr Adolesc Med
146: 932-936
[Abstract]
Wong, R. J.
(1992). The Pharmacological Treatment of Human Immunodeficiency Virus Infection. Journal of Pharmacy Practice
5: 121-130
[Abstract]
